argenex SE $ARGX Shares Bought by Assetmark Inc.

Assetmark Inc. lifted its holdings in shares of argenex SE (NASDAQ:ARGX) by 8.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,818 shares of the company’s stock after purchasing an additional 791 shares during the quarter. Assetmark Inc.’s holdings in argenex were worth $7,242,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Bessemer Group Inc. grew its holdings in shares of argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares in the last quarter. MAI Capital Management boosted its position in argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after buying an additional 78 shares during the period. Mather Group LLC. acquired a new position in shares of argenex in the third quarter worth $50,000. TD Private Client Wealth LLC increased its position in shares of argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock worth $63,000 after acquiring an additional 75 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Down 1.4%

Shares of ARGX stock opened at $821.96 on Tuesday. The stock’s 50-day moving average price is $834.55 and its 200 day moving average price is $803.03. The stock has a market capitalization of $50.86 billion, a PE ratio of 35.29, a price-to-earnings-growth ratio of 0.71 and a beta of 0.37. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Citigroup lowered their target price on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. TD Cowen boosted their price objective on argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Morgan Stanley raised their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Wells Fargo & Company lifted their price target on shares of argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $986.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.